Pulmonary Langerhans cell Histiocytosis

S. Harari, A. Comel

Research output: Contribution to journalArticle

Abstract

Pulmonary Langerhans cell Histiocytosis is a rare granulomatous disease affecting both sexes, with greater incidence in the second and third decades of life; smoking appears to be the most important risk factor. Its etiology is unknown, although there are data indicating an uncontrolled immune response as possible cause, sustained by the Langerhans cells, antigen presenting cells for T lymphocytes, and their accumulation in the distal bronchioles; these cells express on their surface the CD1a and CD1c antigens, and the B7 molecule, essential for activating quiescent T lymphocytes. In its evolution the granuloma is characterized by the progressive reduction in the LC number, with the increase of fibrosis, surrounding and destroying the bronchiolar lumen; the remaining of the lumen, or the traction exerted by fibrous tissue on the adjacent alveolar spaces leads to the cyst development. Vascular involvement occurs frequently, and may explain the onset of pulmonary hypertension in advanced cases of the disease. The disease may be asymptomatic, or it may present with aspecific respiratory signs and symptoms, and has characteristic radiological findings, being included in the group of cysticaerial parenchymal alterations. The diagnosis could be suggested by the finding of a number of LC in BAL greater than 5%. Different therapies have been proposed, but it seems that the most important measure is smoking cessation.

Original languageEnglish
Pages (from-to)253-262
Number of pages10
JournalSarcoidosis Vasculitis and Diffuse Lung Diseases
Volume18
Issue number3
Publication statusPublished - 2001

Fingerprint

Langerhans Cell Histiocytosis
Respiratory Signs and Symptoms
B7 Antigens
T-Lymphocytes
Bronchioles
Dimercaprol
Lung
Langerhans Cells
Traction
Antigen-Presenting Cells
Smoking Cessation
Rare Diseases
Granuloma
Pulmonary Hypertension
Blood Vessels
Cysts
Fibrosis
Smoking
Incidence
Therapeutics

Keywords

  • B7 molecule
  • Birbeck granules
  • CD1a
  • CD1c
  • Dendritic cells
  • Histiocytosis
  • Langerhans cells
  • Pulmonary cysts
  • S100 protein

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Pulmonary Langerhans cell Histiocytosis. / Harari, S.; Comel, A.

In: Sarcoidosis Vasculitis and Diffuse Lung Diseases, Vol. 18, No. 3, 2001, p. 253-262.

Research output: Contribution to journalArticle

@article{3cfc8223d91e4b4db7da97751804bbd8,
title = "Pulmonary Langerhans cell Histiocytosis",
abstract = "Pulmonary Langerhans cell Histiocytosis is a rare granulomatous disease affecting both sexes, with greater incidence in the second and third decades of life; smoking appears to be the most important risk factor. Its etiology is unknown, although there are data indicating an uncontrolled immune response as possible cause, sustained by the Langerhans cells, antigen presenting cells for T lymphocytes, and their accumulation in the distal bronchioles; these cells express on their surface the CD1a and CD1c antigens, and the B7 molecule, essential for activating quiescent T lymphocytes. In its evolution the granuloma is characterized by the progressive reduction in the LC number, with the increase of fibrosis, surrounding and destroying the bronchiolar lumen; the remaining of the lumen, or the traction exerted by fibrous tissue on the adjacent alveolar spaces leads to the cyst development. Vascular involvement occurs frequently, and may explain the onset of pulmonary hypertension in advanced cases of the disease. The disease may be asymptomatic, or it may present with aspecific respiratory signs and symptoms, and has characteristic radiological findings, being included in the group of cysticaerial parenchymal alterations. The diagnosis could be suggested by the finding of a number of LC in BAL greater than 5{\%}. Different therapies have been proposed, but it seems that the most important measure is smoking cessation.",
keywords = "B7 molecule, Birbeck granules, CD1a, CD1c, Dendritic cells, Histiocytosis, Langerhans cells, Pulmonary cysts, S100 protein",
author = "S. Harari and A. Comel",
year = "2001",
language = "English",
volume = "18",
pages = "253--262",
journal = "Sarcoidosis Vasculitis and Diffuse Lung Diseases",
issn = "1124-0490",
publisher = "Mattioli 1885 S.p.A.",
number = "3",

}

TY - JOUR

T1 - Pulmonary Langerhans cell Histiocytosis

AU - Harari, S.

AU - Comel, A.

PY - 2001

Y1 - 2001

N2 - Pulmonary Langerhans cell Histiocytosis is a rare granulomatous disease affecting both sexes, with greater incidence in the second and third decades of life; smoking appears to be the most important risk factor. Its etiology is unknown, although there are data indicating an uncontrolled immune response as possible cause, sustained by the Langerhans cells, antigen presenting cells for T lymphocytes, and their accumulation in the distal bronchioles; these cells express on their surface the CD1a and CD1c antigens, and the B7 molecule, essential for activating quiescent T lymphocytes. In its evolution the granuloma is characterized by the progressive reduction in the LC number, with the increase of fibrosis, surrounding and destroying the bronchiolar lumen; the remaining of the lumen, or the traction exerted by fibrous tissue on the adjacent alveolar spaces leads to the cyst development. Vascular involvement occurs frequently, and may explain the onset of pulmonary hypertension in advanced cases of the disease. The disease may be asymptomatic, or it may present with aspecific respiratory signs and symptoms, and has characteristic radiological findings, being included in the group of cysticaerial parenchymal alterations. The diagnosis could be suggested by the finding of a number of LC in BAL greater than 5%. Different therapies have been proposed, but it seems that the most important measure is smoking cessation.

AB - Pulmonary Langerhans cell Histiocytosis is a rare granulomatous disease affecting both sexes, with greater incidence in the second and third decades of life; smoking appears to be the most important risk factor. Its etiology is unknown, although there are data indicating an uncontrolled immune response as possible cause, sustained by the Langerhans cells, antigen presenting cells for T lymphocytes, and their accumulation in the distal bronchioles; these cells express on their surface the CD1a and CD1c antigens, and the B7 molecule, essential for activating quiescent T lymphocytes. In its evolution the granuloma is characterized by the progressive reduction in the LC number, with the increase of fibrosis, surrounding and destroying the bronchiolar lumen; the remaining of the lumen, or the traction exerted by fibrous tissue on the adjacent alveolar spaces leads to the cyst development. Vascular involvement occurs frequently, and may explain the onset of pulmonary hypertension in advanced cases of the disease. The disease may be asymptomatic, or it may present with aspecific respiratory signs and symptoms, and has characteristic radiological findings, being included in the group of cysticaerial parenchymal alterations. The diagnosis could be suggested by the finding of a number of LC in BAL greater than 5%. Different therapies have been proposed, but it seems that the most important measure is smoking cessation.

KW - B7 molecule

KW - Birbeck granules

KW - CD1a

KW - CD1c

KW - Dendritic cells

KW - Histiocytosis

KW - Langerhans cells

KW - Pulmonary cysts

KW - S100 protein

UR - http://www.scopus.com/inward/record.url?scp=0034835037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034835037&partnerID=8YFLogxK

M3 - Article

C2 - 11587096

AN - SCOPUS:0034835037

VL - 18

SP - 253

EP - 262

JO - Sarcoidosis Vasculitis and Diffuse Lung Diseases

JF - Sarcoidosis Vasculitis and Diffuse Lung Diseases

SN - 1124-0490

IS - 3

ER -